A phase 1/2 trial of WJ22096 in advanced solid tumours, run by Nanjing Jingao biomidical technology Co. Ltd., now recruiting.
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors is a phase 1/2 interventional study registered as NCT07253116 by Nanjing Jingao biomidical technology Co. Ltd., with 20 participants planned, started 2025-11-20 and due to reach its primary completion in 2028-11-30. Interventions recorded: WJ22096.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.